VytlOne at 100: A Century of Redefining the Pharmacy Landscape

PLANO, TX – January 13, 2026 – By Tyler Flores

A century ago, in the historic Fisk Building in downtown Amarillo, Texas, a single community pharmacy opened its doors. Today, that local business, now known as VytlOne, is celebrating its 100th anniversary, having transformed into what it claims is the nation's only independent, fully integrated total pharmacy solutions partner. The milestone marks not just longevity, but a remarkable journey of adaptation and strategic evolution in a healthcare industry that bears little resemblance to that of 1926.

From its origins as Maxor Pharmacy, founded by Howard Guy Maxfield and Samuel Orr, the company has navigated a century of change, moving far beyond the traditional role of dispensing medication. Its centennial celebration highlights a strategic pivot from a local provider to a comprehensive national partner for hospitals and health systems, a move that positions it uniquely in a market dominated by corporate giants.

A Century of Strategic Evolution

VytlOne's story is one of deliberate transformation. For decades, the company, then known as Maxor, steadily grew from its retail roots into a national healthcare services organization. It built a reputation for expertise in complex areas like long-term care pharmacy services and managed care pharmacy operations, laying the groundwork for a more integrated future.

The most significant shifts, however, have occurred in recent years. A pivotal moment came in early 2025 with the strategic combination of Maxor and ProxsysRx, a move that coincided with the appointment of Kim Tsoumakas as Chief Executive Officer. This merger was followed by a comprehensive rebrand in June 2025, when the company shed the Maxor name to become VytlOne. According to the company, the new name was chosen to reflect the vital role of its pharmacy expertise and its commitment to operating as one unified team with its healthcare partners.

This evolution was fueled by strategic investments under the ownership of private equity firm BPOC. The firm guided Maxor through key acquisitions, including a specialty pharmacy, a pharmaceutical rebate aggregator, and a Pharmacy Benefit Manager (PBM). These moves, coupled with investments in a new mail-order facility and significant IT infrastructure upgrades, were instrumental in building the comprehensive, integrated platform that defines VytlOne today.

Carving a Niche in a Consolidated Market

VytlOne's central claim—that it is the 'nation's only independent, fully integrated total pharmacy solutions partner'—is its key differentiator in a heavily consolidated industry. The pharmacy services landscape, particularly the PBM sector, is dominated by three behemoths: CVS Caremark (part of CVS Health), Express Scripts (part of Cigna's Evernorth), and OptumRx (part of UnitedHealth Group). Together, they control an estimated 80% of the market.

These major players are characterized by deep vertical integration, meaning they often own the PBM, the specialty pharmacy, the mail-order pharmacy, and the health insurance plan. This structure has drawn intense scrutiny from regulators and lawmakers over concerns about potential conflicts of interest, opaque pricing, and practices that may stifle competition from independent pharmacies.

It is against this backdrop that VytlOne has defined its identity. By remaining independent from a major insurer or retail pharmacy chain, the company argues it can offer unbiased partnership. Its integrated model combines a full suite of services—pharmacy operations management, 340B program administration, specialty pharmacy, PBM services, and patient affordability solutions—under one roof. This allows a health system to work with a single partner for a wide array of complex pharmacy needs, rather than contracting with multiple, disparate vendors.

For mission-driven hospitals and health systems, this model promises alignment. The company's stated goal is to function as an extension of its clients' teams, helping them navigate complexities, improve patient outcomes, and, crucially, unlock new revenue streams that can be reinvested directly into patient care and community health initiatives.

The Modern Pharmacy Partner for Mission-Driven Health Systems

The demand for a partner like VytlOne is driven by the immense pressures facing modern healthcare providers. Hospitals, particularly non-profit and safety-net systems, are grappling with razor-thin margins, rising drug costs, and an increasingly complex regulatory environment.

Services like 340B program management have become critical. The 340B Drug Pricing Program allows eligible providers that serve vulnerable patient populations to purchase outpatient drugs at a significant discount. For these entities, the savings are not just a line item but a financial lifeline that funds essential services. However, compliance is notoriously complex. VytlOne's integrated approach helps these providers manage compliance while maximizing the program's financial benefits, turning the pharmacy from a cost center into a source of sustainable revenue.

This focus on financial health is directly linked to patient outcomes. By streamlining pharmacy operations, improving medication adherence through patient affordability programs, and managing high-cost specialty drugs more effectively, the integrated model aims to enhance the quality of care. This philosophy is at the core of the company's current vision.

"Our past is the foundation, and our future is strong, driven by one team and one vision," said Kim Tsoumakas, CEO of VytlOne, in a statement. "Guided by our values—Integrity, Excellence for Partners, Purpose, Authenticity, and One Team—we will continue to make a meaningful impact on the lives we touch every day."

As VytlOne looks toward its next century, it remains focused on innovation and collaboration. The company's journey from a single corner pharmacy in Amarillo to a national, independent solutions partner reflects a profound shift in the role of pharmacy itself—no longer just a dispenser of medicine, but a strategic pillar in the financial and clinical success of the entire healthcare ecosystem.